The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US patients.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
At the heart of the biotech deal is a relatively new drug technology called PD-1/VEGF bispecific antibodies.